Press release from Companies
Published: 2021-08-19 08:00:00
Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1 April – 30 June 2021. The second quarter report is available as an attached document to this press release and on www.cessatech.com under Investor, ‘Filings & Reports’. The company is on track with planned activities, has completed recruitment for the bioavailability trial 0204 and is ready to initiate recruitment of trial 0206 - a trial to investigate the pharmacokinetics in children aged 1-17 undergoing elective surgical procedures.
Second quarter 2021 (1 April – 30 June):
**Solidity: Total equity divided by total capital and liability.
Highlights during second quarter 2021
For more information about Cessatech, please contact:
Jes Trygved, CEO
Phone: +45 9387 2309
E-mail: jes.trygved@cessatech.com
www.cessatech.com
About Cessatech A/S:
Cessatech’s business model offers unique, scalable economic value creation by identifying and developing drugs with a short time to market and risk-reduced profile. The drugs that are developed by Cessatech should be proven effective in adults and represent a medical unmet need in children where a focused development plan can be applied for documenting good effect in children. Cessatech’s first product and lead asset, CT001, is an analgesic non-invasive nasal spray for children aged 1-17 years that experience acute pain or pain related to medical procedures.